Hepatobiliary Adverse Events Associated With the <scp>KRAS p.G12C</scp> Inhibitor Sotorasib
These findings highlight the hepatobiliary risks associated with sotorasib and underscore the importance of closely monitoring liver function in patients who are using the medication. This is particularly crucial for patients with hepatobiliary cancers, as disease progression and adverse events could be misinterpreted.
Authors
- Connor Frey (ORCID: https://orcid.org/0000-0002-4080-3030)
Institutions
- University of British Columbia (CA)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1002/pds.70104
- Citations
- 3
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 4.88